Analysts Set Boston Scientific Corporation (NYSE:BSX) Price Target at $71.62

Shares of Boston Scientific Corporation (NYSE:BSX) have been given an average recommendation of “Moderate Buy” by the thirty-one research firms that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and twenty-four have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $71.6154.

BSX has been the topic of a number of research analyst reports. TD Cowen cut their price objective on shares of Boston Scientific from $61.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Canaccord Genuity Group dropped their target price on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Mizuho cut their target price on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Citigroup reduced their price target on shares of Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Finally, Zacks Research downgraded Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th.

Insider Activity

In related news, Director David C. Habiger bought 2,100 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were bought at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the transaction, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Michael F. Mahoney acquired 186,240 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This represents a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 204,322 shares of company stock worth $9,939,221 in the last three months. 0.34% of the stock is currently owned by company insiders.

Institutional Trading of Boston Scientific

Several large investors have recently bought and sold shares of BSX. Vanguard Group Inc. grew its stake in Boston Scientific by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after acquiring an additional 1,436,550 shares during the last quarter. BlackRock Inc. acquired a new position in Boston Scientific during the second quarter worth about $5,534,781,000. State Street Corp raised its position in Boston Scientific by 1.4% during the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after acquiring an additional 920,495 shares during the last quarter. Capital World Investors lifted its holdings in shares of Boston Scientific by 1.9% in the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after purchasing an additional 502,627 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $2,199,395,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Up 0.7%

BSX opened at $51.78 on Tuesday. Boston Scientific has a one year low of $42.20 and a one year high of $109.50. The company has a market cap of $75.04 billion, a P/E ratio of 20.96, a PEG ratio of 1.12 and a beta of 0.56. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The business’s 50-day simple moving average is $46.00 and its 200-day simple moving average is $59.40.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm’s revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities research analysts expect that Boston Scientific will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has authorized a stock buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.